PE20190403A1 - Metodos para tratar el cancer de prostata - Google Patents

Metodos para tratar el cancer de prostata

Info

Publication number
PE20190403A1
PE20190403A1 PE2019000269A PE2019000269A PE20190403A1 PE 20190403 A1 PE20190403 A1 PE 20190403A1 PE 2019000269 A PE2019000269 A PE 2019000269A PE 2019000269 A PE2019000269 A PE 2019000269A PE 20190403 A1 PE20190403 A1 PE 20190403A1
Authority
PE
Peru
Prior art keywords
prostate cancer
methods
treat prostate
brca
human
Prior art date
Application number
PE2019000269A
Other languages
English (en)
Inventor
Rebecca Hawkins
Linda Snyder
Douglas H Yamada
Marco Gottardis
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20190403A1 publication Critical patent/PE20190403A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

Referido a un metodo para tratar el cancer de prostata en un ser humano que comprende en administrar una cantidad segura y eficaz de niraparib; en donde el cancer es metastasico, resistente a la castracion o resistente a los antiandrogenos; y en donde el ser humano porta al menos una anomalia en la reparacion del ADN seleccionada de BRCA-1, BRCA-2, FANCA, PALB2, CHEK2, BRIP1, HDAC2 y ATM.
PE2019000269A 2016-07-29 2017-07-28 Metodos para tratar el cancer de prostata PE20190403A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662368466P 2016-07-29 2016-07-29
US201662369239P 2016-08-01 2016-08-01

Publications (1)

Publication Number Publication Date
PE20190403A1 true PE20190403A1 (es) 2019-03-13

Family

ID=59649991

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000269A PE20190403A1 (es) 2016-07-29 2017-07-28 Metodos para tratar el cancer de prostata

Country Status (20)

Country Link
US (8) US20180028521A1 (es)
EP (1) EP3490560A1 (es)
JP (2) JP2019522032A (es)
KR (1) KR20190033599A (es)
CN (1) CN109640991A (es)
AU (2) AU2017302660B2 (es)
BR (1) BR112019001398A2 (es)
CA (1) CA3031705A1 (es)
CO (1) CO2019000753A2 (es)
DO (1) DOP2019000019A (es)
IL (1) IL264443A (es)
MA (1) MA45780A (es)
MX (1) MX2019001224A (es)
NI (1) NI201900009A (es)
PE (1) PE20190403A1 (es)
PH (1) PH12019500135A1 (es)
SG (1) SG11201900361RA (es)
SV (1) SV2019005822A (es)
UA (1) UA124972C2 (es)
WO (1) WO2018023017A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
JP2019522032A (ja) 2016-07-29 2019-08-08 ヤンセン ファーマシューティカ エヌ．ベー． 前立腺癌の治療方法
CN111801117A (zh) * 2017-12-27 2020-10-20 特沙诺有限公司 治疗癌症的方法
JP7456942B2 (ja) * 2018-05-16 2024-03-27 オンクターナル セラピューティクス，インコーポレイテッド 選択的アンドロゲン受容体分解剤（ｓａｒｄ）リガンドおよびその使用方法
US20210340122A1 (en) * 2018-09-05 2021-11-04 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
WO2023001746A1 (en) * 2021-07-19 2023-01-26 Janssen Pharmaceutica Nv Treatment of metastatic castration-resistant prostate cancer with niraparib

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2109608B1 (en) 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
CN106008460B (zh) 2008-01-08 2022-08-12 默沙东公司 2-{4-[(3s)-哌啶-3-基]苯基}-2h-吲唑-7-羧酰胺的药学可接受的盐
CA2723590C (en) 2008-05-07 2017-06-27 Cardioxyl Pharmaceuticals Inc. Novel nitroso compounds as nitroxyl donors and methods of use thereof
WO2012009475A1 (en) 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
WO2014089324A1 (en) 2012-12-07 2014-06-12 Calitor Sciences, Llc Substituted cyclic compounds and methods of use
EP3230472A4 (en) 2014-12-08 2018-06-13 Myriad Genetics, Inc. Methods and materials for predicting response to niraparib
JP2019522032A (ja) * 2016-07-29 2019-08-08 ヤンセン ファーマシューティカ エヌ．ベー． 前立腺癌の治療方法
JOP20190244A1 (ar) 2017-04-13 2019-10-13 Janssen Pharmaceutica Nv تركيبة علاجية لسرطان البروستاتا

Also Published As

Publication number Publication date
JP2022122920A (ja) 2022-08-23
BR112019001398A2 (pt) 2019-05-07
SG11201900361RA (en) 2019-02-27
US20230149380A1 (en) 2023-05-18
US20190022079A1 (en) 2019-01-24
US20230078160A1 (en) 2023-03-16
CO2019000753A2 (es) 2019-02-08
US20220071980A1 (en) 2022-03-10
IL264443A (en) 2019-02-28
CN109640991A (zh) 2019-04-16
MA45780A (fr) 2019-06-05
DOP2019000019A (es) 2019-09-30
US20240000766A1 (en) 2024-01-04
NI201900009A (es) 2019-05-10
EP3490560A1 (en) 2019-06-05
MX2019001224A (es) 2019-06-03
US11207311B2 (en) 2021-12-28
PH12019500135A1 (en) 2019-10-28
UA124972C2 (uk) 2021-12-22
KR20190033599A (ko) 2019-03-29
SV2019005822A (es) 2019-03-28
US20230098047A1 (en) 2023-03-30
AU2023202813A1 (en) 2023-05-25
AU2017302660B2 (en) 2023-04-20
JP2019522032A (ja) 2019-08-08
WO2018023017A1 (en) 2018-02-01
US20180028521A1 (en) 2018-02-01
US20220071979A1 (en) 2022-03-10
AU2017302660A1 (en) 2019-01-24
CA3031705A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
PE20190403A1 (es) Metodos para tratar el cancer de prostata
AR126205A2 (es) Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
BR112018073329A2 (pt) combinação, composição farmacêutica, kit, método para tratar câncer, método para reduzir um nível de células, método para aumentar a atividade, método para aumentar a citotoxicidade, método para reduzir metástase
BR112017008628A2 (pt) terapia de combinação compreendendo agonistas de ligação a ox40 e inibidores de tigit
WO2016025635A3 (en) Combination therapy for treating cancer
BR112017000301A2 (pt) tratamento de leucemia com inibidores de histona desacetilase
ZA201905222B (en) Combination treating prostate cancer, pharmaceutical composition and treatment method
BR112017028530A2 (pt) terapia combinada para tratamento de cânceres hematológicos e tumores sólidos
PE20180673A1 (es) Tratamiento contra el cancer por manipulacion de la microflora comensal
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
MX2020008906A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
ES2422605T3 (es) Anticuerpo contra klotho-beta para utilizar en el tratamiento de tumores, cáncer o trastornos proliferativos celulares
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
SG10201902664RA (en) Combination therapy for treating cancer
BR112018012255A2 (pt) método para tratar câncer
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
CL2011000916A1 (es) Uso de una combinacion de un inhibidor de proteasoma epoxicetona peptidica o una sal farmaceutica aceptable del mismo, y uno o mas de otros agentes terapeuticos para tratar el cancer.
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
ECSP11011490A (es) Uso de sintético y biológico fungicidas en combinación para controlar hongos dañinos
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
BR112015023203A2 (pt) métodos para tratamento de câncer, para aumentar a eficiência de um tratamento de câncer, para retardar e/ou prevenir o desenvolvimento de câncer, para tratar um indivíduo com câncer, para aumentar a sensibilidade para um agente de terapia para câncer, para estender um período de sensibilidade e para estender a duração da resposta para uma terapia para câncer, e usos
NI201500150A (es) TRATAMIENTO DE CÁNCER CON DIHIDROPIRAZINO-PIRAZINAS×Se proporcionan en la presente método
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion